Purpose Although direct oral anticoagulants are effective and safe in preventing stroke in
atrial fibrillation (AF) patients with low body weight, data remain limited in AF patients with …

Objective To investigate the association between body mass index (BMI) and oral
anticoagulant (OAC) prescription in atrial fibrillation (AF). Methods Patients with newly …

Background: Elderly patients are at high risk of both ischaemic and bleeding events, and the
low body weight is considered a risk factor for major bleeding in atrial fibrillation (AF) …

Data on the impact of morbid obesity (body mass index [BMI]≥ 40 kg/m2) on the
pharmacokinetics (PK), pharmacodynamics (PD) of direct oral anticoagulants (DOACs) are …

Background Several observational studies have shown that the inappropriate dosing use of
direct oral anticoagulants (DOACs) in atrial fibrillation (AF) that does not conform to …

Although obesity is associated with the development and progression of atrial fibrillation
(AF), an obesity paradox may be present, illustrated by seemingly protective effects of …

Purpose: There is limited clinical data evaluating anticoagulation with the direct oral
anticoagulants (DOACs) in morbidly obese patients. We sought to examine the efficacy in …

Direct acting non-Vitamin K antagonist oral anticoagulants (NOAC) are characterized by a
fixed dosing regimen. Despite the potential for relative underdosing due to large distribution …

Anticoagulation therapy is recommended for patients with non-valvular atrial fibrillation
(NVAF) and an increased risk of stroke. Although apixaban showed superiority over warfarin …

Background: Limited clinical data exist describing the use of direct-acting oral
anticoagulants (DOACs) in patients with body mass index (BMI)> 40 kg/m2 or body weight> …